IC
Ikarian Capital Portfolio holdings
AUM
$302M
This Quarter Return
-1.15%
1 Year Return
+65.21%
3 Year Return
+441.33%
5 Year Return
+548.26%
10 Year Return
–
AUM
$320M
AUM Growth
+$320M
(-13%)
Cap. Flow
+$6.14M
Cap. Flow
% of AUM
1.92%
Top 10 Holdings %
Top 10 Hldgs %
52.44%
Holding
116
New
16
Increased
13
Reduced
23
Closed
13
Top Buys
| 1 |
Enliven Therapeutics
ELVN
|
$13.7M |
| 2 |
Amgen
AMGN
|
$12M |
| 3 |
Sarepta Therapeutics
SRPT
|
$8.11M |
| 4 |
Viking Therapeutics
VKTX
|
$7.33M |
| 5 |
Cartesian Therapeutics
RNAC
|
$6.55M |
Top Sells
| 1 |
TECX
Tectonic Therapeutic, Inc. Common Stock
TECX
|
$11.4M |
| 2 |
Corbus Pharmaceuticals
CRBP
|
$11.3M |
| 3 |
ALPN
Alpine Immune Sciences, Inc. Common Stock
ALPN
|
$10.4M |
| 4 |
Praxis Precision Medicines
PRAX
|
$10.3M |
| 5 |
Alnylam Pharmaceuticals
ALNY
|
$7.7M |
Sector Composition
| 1 | Healthcare | 99.74% |
| 2 | Real Estate | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Sarepta Therapeutics
SRPT
$1.78B
| $32.2M | 5.6% | 203,612 +51,334 | +34% | +$8.11M |
|
2
Crinetics Pharmaceuticals
CRNX
$2.92B
| $26.4M | 4.59% | 588,818 -54,933 | -9% | -$2.46M |
|
3
Tarsus Pharmaceuticals
TARS
$2.47B
| $21.8M | 3.79% | 800,277 +90,000 | +13% | +$2.45M |
|
4
Soleno Therapeutics
SLNO
$3.6B
| $18.2M | 3.17% | 445,451 -119,960 | -21% | -$4.89M |
|
|
5
Corbus Pharmaceuticals
CRBP
$115M
| $14M | 2.44% | 309,540 -249,731 | -45% | -$11.3M |
|
|
6
Enliven Therapeutics
ELVN
$1.2B
| $13.7M | 2.39% | +586,552 | New | +$13.7M |
|
|
7
Amgen
AMGN
$155B
| $12M | 2.08% | +38,300 | New | +$12M |
|
8
Nuvalent
NUVL
$5.52B
| $11.5M | 2% | 151,601 +50,000 | +49% | +$3.79M |
|
9
Cytokinetics
CYTK
$4.23B
| $9.22M | 1.61% | 170,147 +25,000 | +17% | +$1.35M |
|
10
Nurix Therapeutics
NRIX
$714M
| $9.19M | 1.6% | 440,500 +140,500 | +47% | +$2.93M |
|
11
BridgeBio Pharma
BBIO
$9.89B
| $8.41M | 1.47% | 332,013 +50,000 | +18% | +$1.27M |
|
12
Catalyst Pharmaceutical
CPRX
$2.52B
| $8.03M | 1.4% | 518,386 | – | – |
|
|
13
Viking Therapeutics
VKTX
$3.04B
| $7.33M | 1.28% | +138,262 | New | +$7.33M |
|
14
Immunovant
IMVT
$2.56B
| $7.31M | 1.27% | 276,925 | – | – |
|
|
15
Cartesian Therapeutics
RNAC
$261M
| $6.55M | 1.14% | +242,370 | New | +$6.55M |
|
|
SLRN
16
DELISTED
ACELYRIN
SLRN
| $6.51M | 1.13% | 1,475,074 -89,266 | -6% | -$394K |
|
17
Neurocrine Biosciences
NBIX
$13.8B
| $5.51M | 0.96% | +40,000 | New | +$5.51M |
|
18
Pyxis Oncology
PYXS
$79.4M
| $5.5M | 0.96% | 1,662,408 | – | – |
|
19
Arcutis Biotherapeutics
ARQT
$1.86B
| $4.55M | 0.79% | 489,642 -100,000 | -17% | -$930K |
|
20
Rocket Pharmaceuticals
RCKT
$354M
| $4.24M | 0.74% | 197,096 -100,000 | -34% | -$2.15M |
|
21
Xenon Pharmaceuticals
XENE
$2.98B
| $4.18M | 0.73% | 107,187 | – | – |
|
22
CervoMed
CRVO
$83.7M
| $4.06M | 0.71% | 237,345 | – | – |
|
23
Rezolute
RZLT
$619M
| $3.89M | 0.68% | +903,744 | New | +$3.89M |
|
|
CYBN
24
Cybin
CYBN
$176M
| $3.78M | 0.66% | 13,953,488 | – | – |
|
|
LENZ
25
LENZ Therapeutics
LENZ
$1.1B
| $3.54M | 0.62% | 204,513 +119,513 | +141% | +$2.07M |
|